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Bone disease in children and adolescents undergoing successful renal
transplantation. Little is known about the extent and severity of bone
disease in children undergoing successful renal transplantation. To ad-
dress this issue, 47 patients with stable renal function 3.2 6 1.7 years after
transplantation (Tx) underwent iliac crest bone biopsy. The mean age of
patients was 12 6 2.0 years; 36 had received cadaveric renal grafts,
whereas 11 had undergone living-related Tx. Immunosuppressive drugs
included cyclosporine 0.176 0.4 mg/kg/day, prednisone 7.5 6 2.1 mg/kg/
day, and either azathioprine 1.6 6 0.9 mg/kg/day or mycophenolate
mofetil 30 6 3 mg/kg/day. In addition to quantitative bone histomorphom-
etry, the bone mineral content (BMC) of the lumbar spine was measured
by dual energy X-ray absorptiometry (DXA) in 24/47 patients. Thirty-one
transplant recipients had normal bone formation (N-Bfr), 11 had mild
hyperparathyroidism (HPT) and 5 had adynamic skeletal lesions (AD).
The interval since Tx, duration of dialysis before Tx and cumulative
prednisone dose did not differ among groups. Trabecular bone area was
highest in subjects with HPT. Unexpectedly, eroded bone perimeter
exceeded normal reference values both in patients with AD and in those
with N-Bfr; the osteoid area and osteoid perimeter were also elevated in
these two groups. Hyperparathyroidism improved or resolved after Tx in
all 14 subjects with this skeletal lesion prior to Tx, but one patient
developed AD after Tx. Bone histology did not change after Tx in those
with N-Bfr during regular dialysis, but bone formation increased after Tx
in two of three patients with AD during regular dialysis. Z-scores for
height in pre-pubertal patients after Tx were below age-appropriate values
in each histologic subgroup, but values did not differ among groups.
Z-scores for bone mineral content at the lumbar spine were also less than
age-predicted values, 20.67 6 1.2. After adjusting for the degree of
growth retardation, height-adjusted z-scores for lumbar spine BMC after
Tx were above normal in all three histologic groups (0.68 6 1.0). The
results suggest that reductions in bone mass and post-transplant osteopo-
rosis are not prominent findings in pediatric renal transplant recipients
when the influence of growth retardation on bone mass measurements by
DXA is carefully considered.
Successful kidney transplantation corrects many of the meta-
bolic abnormalities that lead to the development of renal os-
teodystrophy in children with chronic renal failure. Phosphorus
retention and hyperphosphatemia resolve promptly, 1,25-dihy-
droxyvitamin D production is restored, and intestinal calcium
absorption improves when adequate renal function is re-estab-
lished [1]. As such, several key factors that increase parathyroid
hormone secretion and promote parathyroid gland hyperplasia in
those with chronic renal failure either partially or completely
disappear after successful renal transplantation. Despite such
changes, osteoporosis, growth failure, spontaneous fractures and
avascular necrosis of bone are prominent clinical problems in
pediatric renal transplant recipients [2–6].
Secondary hyperparathyroidism remains the most common
skeletal lesion of renal osteodystrophy in children undergoing
regular dialysis [7, 8]. Julian and colleagues reported that the
histologic features of secondary hyperparathyroidism resolved
within the first six months after renal transplantation in adults,
and bone formation decreased substantially [9]. These changes
were associated, however, with reductions in bone mass as deter-
mined by dual energy X-ray absorptiometry (DXA) [9]. Whether
similar events occur in children undergoing renal transplantation
has not been determined. Also, Velasquez-Forero and co-workers
found adynamic lesions of bone despite moderately elevated
serum parathyroid hormone (PTH) levels in 12 of 16 adult kidney
transplant recipients evaluated seven years after successful renal
transplantation [10]. Both corticosteroids and cyclosporine can
influence bone formation and turnover [11–14], but the preva-
lence of adynamic bone in pediatric renal transplant recipients
remains uncertain.
The spectrum of renal bone disease has been described in some
detail in children undergoing regular dialysis [7]; however, there is
limited information about the prevalence and histopathologic
type of bone disease in pediatric renal transplant recipients. The
current study was therefore undertaken to characterize the histo-
logic features of bone in children undergoing successful renal
transplantation and to document the evolution of renal osteodys-
trophy after successful transplantation in children previously
managed by peritoneal dialysis. In addition, the relationship
between the type of bone disease and bone loss after transplan-
tation was examined using dual energy X-ray absorptiometry
(DXA) to measure bone mass.
METHODS
Study subjects
All patients followed at the UCLA pediatric renal transplant
clinic were considered as potential candidates for study. Approx-
imately 250 renal transplant recipients are seen regularly at this
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facility. Patients with stable renal function for at least one year
following transplantation who agreed to undergo bone biopsy
were entered into the study. A total of forty-seven patients were
evaluated: 20 patients were Caucasian, 23 were of Hispanic origin,
two were African-American and two were Asian. The mean age of
patients was 12 6 2.0 years, range 4 to 20 years; there were 31 boys
and 16 girls. The interval since transplantation at entry into study
was 3.2 6 1.7 years. Thirty-six patients had received cadaveric
renal allografts, whereas 11 had undergone living-related trans-
plantation.
Causes of renal failure leading to treatment with regular dialysis
included obstructive uropathy/reflux nephropathy (N 5 16), renal
dysplasia (N 5 13), glomerulonephritis (N 5 9), cystic disease
(N 5 3), hemolytic-uremic syndrome (N 5 2), congenital ne-
phrotic syndrome (N 5 2), cystinosis (N 5 1) and Alport’s
syndrome (N 5 1). All studies were approved by the UCLA
Human Subject Protection Committee, and informed consent was
obtained from each patient and his/her parent or guardian.
All but two patients received daily oral doses of prednisone at
an average dose of 0.17 6 0.4 mg/kg/day. Two patients were
managed using an alternate-day prednisone dosing regimen. The
average dose of cyclosporine was 7.5 6 2.1 mg/kg/day. As part of
induction therapy, all patients received either monoclonal or
polyclonal anti-T cell medications. Thirty-five patients were given
azathioprine as a third immunosuppressive agent using an average
dose of 1.6 6 0.9 mg/kg/day, whereas 11 patients received
mycophenolate mofetil, 30 6 3 mg/kg/day, together with pred-
nisone and cyclosporine. One patient was managed with pred-
nisone and cyclosporine only. Acute rejection episodes were
treated using a standardized protocol of intravenous methylpred-
nisolone, 10 mg/kg, for three consecutive days.
Forty-two patients received vitamin D therapy, that is, calcitriol,
while undergoing regular maintenance dialysis. After kidney
transplantation, however, study participants did not receive oral
calcium supplements or vitamin D sterols, and none were treated
with anti-convulsant medications.
Prior to renal transplantation, all subjects had been maintained
on regular peritoneal dialysis. The duration of dialysis before
transplantation was 2.4 6 1.1 years. Only calcium-containing,
phosphate-binding agents were used during treatment with regu-
lar dialysis. None of the patients received aluminum-containing
medications, and none had been treated with recombinant human
growth hormone (rhGH). There was no history of skeletal frac-
ture in any of the patients either during maintenance dialysis
therapy or after kidney transplantation.
Bone biopsy and bone histomorphometry
Trans-iliac bone biopsies were obtained after double tetracy-
cline labeling as previously described using a modified Bordier
bone biopsy trephine [7]. Quantitative bone histomorphometry
was done by methods outlined in detail elsewhere [7, 15], and the
terminology established by the Nomenclature Committee of the
American Society for Bone and Mineral Research was used to
report all histomorphometric results [16]. The histomorphometric
criteria used to define the various histologic subgroups of renal
osteodystrophy have been presented in detail elsewhere [7].
In 24 transplant recipients, a bone biopsy had previously been
obtained while the patient was undergoing regular peritoneal
dialysis. The biopsy results after renal transplantation in this
subset of patients were compared to those obtained before
transplantation.
Bone mass measurements
Bone mass was measured by dual energy x-ray absorptiometry
(DXA) in 24 of 47 patients using a Hologic QDR 5000 (Hologic,
Waltham, MA, USA). These subjects were entering a randomized
clinical trial of recombinant human growth hormone (rhGH), and
the results presented were baseline determinations obtained
before starting the therapeutic trial. Bone mass measurements
were not obtained at the time of renal transplantation in any of
the patients. To avoid the confounding effect of differences in the
age of onset of puberty on values for bone mass and body height,
bone mineral content and height are reported only in pre-pubertal
subjects. Height and weight were measured at the time of bone
mass determinations, and standard deviation scores for height
(H-SDS) were calculated. The interval between renal transplan-
tation and bone mass determinations was 3.9 6 1.5 years. Bone
mass was measured at the lumbar spine, and values for bone
mineral content, in g/cm2, reflect values from the first through the
fourth lumbar vertebrae. Results were also expressed as z-scores
relative to mean normal values for subjects of the same age and
gender. All bone mass measurements in renal transplant recipi-
ents were obtained within one month of bone biopsy. Again, all
results for height represent measurements obtained in pre-puber-
tal subjects.
Biochemical determinations
Samples of blood were obtained at the time of bone biopsy for
subsequent measurements of total calcium, phosphorus, creati-
nine, parathyroid hormone, alkaline phosphatase and 1,25-dihy-
droxyvitamin D levels in serum [7]. Parathyroid hormone levels
were measured using a two-site immunoradiometric assay for the
intact molecule [17], and serum 1,25-dihydroxyvitamin D levels
were measured by radioreceptor assay as previously described
(Corning-Nichols, San Juan Capistrano, CA, USA) [18]. Glomer-
ular filtration rate (GFR) was estimated from serum creatinine
values using the Schwartz formula [19].
Statistical analysis
All results are expressed as means 6 standard error. Compar-
isons between or among groups were done using unpaired t-tests,
paired t-tests or one-way analysis of variance with contrasts [20].
Linear regression was done by the method of least squares [20].
RESULTS
Bone histology in renal transplant recipients
Thirty-one of 47 pediatric renal transplant recipients had
normal rates of bone formation documented by quantitative
histomorphometry 3.2 6 1.7 months after renal transplantation;
11 had mild secondary hyperparathyroidism, whereas five had
adynamic lesions of bone. Neither the interval since transplanta-
tion nor the duration of dialysis prior to renal transplantation
differed among the three histologic subgroups (Table 1). The
cumulative dose of prednisone also did not differ among those
with normal bone formation, adynamic lesions of bone or second-
ary hyperparathyroidism (Table 1).
Despite values for bone formation that fell within the normal
range, several static histologic variables were abnormal in many
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transplant recipients with normal bone formation when the results
were compared to data obtained in subjects with normal renal and
parathyroid gland function (Table 2). The eroded bone perimeter
exceeded the upper limit of normal in 21 of 31 subjects, whereas
values for the osteoid area and osteoid perimeter were above the
upper limit of normal in 28 of 31 and 29 of 31 patients,
respectively.
The extent of histologic change in patients with secondary
hyperparathyroidism was rather modest, and thus, none of the
patients had peri-trabecular or marrow fibrosis. The predominant
histomorphometric findings in this subgroup of patients were
increases in osteoid perimeter and in eroded bone perimeter
when the results were compared to normal reference values
(Table 2). As expected, both the extent of double tetracycline-
labeled bone perimeter and the rate of bone formation were
greater than normal in subjects with mild secondary hyperpara-
thyroidism (Table 2). Trabecular bone area was also higher in
patients with secondary hyperparathyroidism than in those with
either adynamic lesions or normal bone formation (Table 2).
Bone formation was reduced in those with adynamic renal
osteodystrophy, but values for osteoid area and osteoid perimeter
exceeded normal reference values in renal transplant recipients
with adynamic skeletal lesions (Table 2). Eroded bone perimeter
was moderately elevated when compared to values in subjects with
normal renal and parathyroid gland function, and osteoid area,
osteoid perimeter and eroded bone perimeter did not differ
between renal transplant recipients with adynamic renal osteodys-
trophy and patients with normal rates of bone formation (Table
2). Indeed, the results for each histologic variable were quite
similar in these two groups (Table 2).
Neither serum creatinine levels nor calculated glomerular fil-
tration rates differed among groups (Table 3). Serum calcium,
phosphorus, alkaline phosphatase and 1,25-dihydroxyvitamin D3
levels also did not differ among the various histologic lesions
(Table 3). Serum parathyroid hormone (PTH) levels ranged from
10 to 200 pg/ml (normal 10 to 65 pg/ml). Eleven of 47 patients had
values that exceeded 65 pg/ml, and four patients had values
greater than 100 pg/ml. Of these, three had normal rates of bone
formation, whereas the fourth had a mild lesion of secondary
hyperparathyroidism.
The serum levels of PTH failed to discriminate among renal
transplant recipients with normal bone formation, adynamic le-
sions or secondary hyperparathyroidism. There was no correlation
between the rate of bone formation and either serum PTH levels
(r 5 0.14) or serum alkaline phosphatase values (r 5 20.05) when
the results for all study subjects were considered. Also, neither
serum PTH (r 5 0.25) nor alkaline phosphatase (r 5 0.15) levels
correlated with eroded bone perimeter.
Change in bone histology after renal transplantation
Bone histology changed substantially in the 24 patients initially
evaluated during maintenance dialysis therapy and again after
successful renal transplantation (Fig. 1). The interval between
biopsies was 4.7 6 3.2 years, and it did not differ among those with
secondary hyperparathyroidism, normal bone formation or ady-
namic lesions on follow-up examination. Age, gender and time
since transplantation also did not differ among groups (Table 1).
Secondary hyperparathyroidism improved or fully resolved
Table 1. Characteristics of pediatric renal transplant recipients with
secondary hyperparathyroidism (2° HPT), normal rates of bone
formation (NL-BFR) and adynamic lesion (AD)
2° HPT
(N 5 11)
NL-BFR
(N 5 31)
AD
(N 5 5)
Age years 11 6 2.0 12 6 2.0 8.0 6 2.0
Gender, M:F 5:6 21:10 5:0
Time on dialysis years 2.5 6 1.2 2.2 6 1.4 2.0 6 0.8
Time since transplant years 3.7 6 1.9 3.0 6 1.4 4.2 6 1.9
Prednisone dose, cumulative g 3.6 6 1.3 4.4 6 2.1 3.9 6 1.3
Table 2. Bone histomorphometry results in renal transplant recipients
with secondary hyperparathyroidism (2° HPT), normal rates of bone
formation (NL-BFR) and adynamic lesion (AD)
2° HPT
(N 5 11)
NL-BFR
(N 5 31)
AD
(N 5 5)
Reference
values,
(N 5 31)
Bone area 30.0 6 3.1a 21.3 6 2.2 18.9 6 1.9b 21.7 6 1.8
[B.Ar.] % (14.6–26.9)
Osteoid area 7.8 6 1.6 6.8 6 1.9 6.6 6 1.8c 2.3 6 1.2
[O.Ar.] % (0.2–5.8)
Osteoid perimeter 43 6 2.7 42 6 4.0 38 6 4.0c 17.9 6 2.9
[O.Pm.] % (4.3–31.7)
Osteoid thickness 12.9 6 1.4a 9.6 6 1.2 9.7 6 1.0b 8.8 6 1.5
[O.Th] mm (4.1–13.1)
Eroded perimeter 6.0 6 1.7e 3.7 6 1.8d 3.9 6 1.8c 2.0 6 0.9
[E.Pm.] % (0.4–3.4)
Double-labeled 13 6 1.9 7.5 6 1.9 0.5 6 0.9 5.4 6 2.0
perimeter [dLS] % (1.6–15.8)
Trabecular number 2.0 6 0.4 1.7 6 5.1 1.6 6 0.5 1.6 6 0.5
[Tb.N.] #/mm (1.1–2.2)
Trabecular width 135 6 5.5 125 6 4.5 119 6 3.7 135 6 5.2
[Tb.Wi.] mm (90–175)
Bone formation rate 830 6 13 360 6 12 28 6 6 273 6 31
[BFR/B.Ar.]
mm2/mm2/day
(93–613)
Reference values were obtained in 31 children with normal renal
function as reported elsewhere [8].
a P , 0.001, 2°HPT vs. NL-BFR
b P , 0.05, AD vs. 2°HPT
c P , 0.01, AD vs. Reference
d P , 0.01, NL-BFR vs. Reference
e P , 0.01, 2°HPT vs. Reference
Table 3. Serum biochemical results and calculated glomerular filtration
rate (GFR) grouped according to histological subtype in renal
transplant recipients
Serum biochemical
parameters
2° HPT
(N 5 11)
NL-BFR
(N 5 31)
AD
(N 5 5)
Serum calcium 9.5 6 1.2 9.5 6 0.7 9.5 6 0.3
mg/dl
Serum phosphorus 4.0 6 0.9 4.5 6 0.9 4.3 6 0.9
mg/dl
Serum alkaline phosphatase 230 6 10 232 6 10 234 6 10
IU/liter
Serum parathyroid hormone 56 6 5 55 6 6 50 6 4
pg/ml
Serum 1,25 (OH)2D3 37 6 4 40 6 4 42 6 5
pg/ml
Serum creatinine 1.0 6 0.3 1.3 6 0.6 1.0 6 0.4
mg/dl
Glomerular filtration rate 63 6 14 53 6 12 56 6 14
ml/min/1.73 m2
Abbreviations are: 2°HPT, secondary hyperparathyroidism; NL-BFR,
normal rates of bone formation, AD, adynamic bone lesion.
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after renal transplantation in all 14 subjects with this skeletal
lesion prior to transplantation. One patient, however, developed
adynamic renal osteodystrophy (Fig. 1). The histologic findings in
seven patients with normal bone formation during treatment with
regular peritoneal dialysis did not change after renal transplanta-
tion (Fig. 1). In contrast, bone formation increased following
transplantation in two of three patients with adynamic renal
osteodystrophy when initially evaluated during regular peritoneal
dialysis (Fig. 1).
Serum PTH levels decreased markedly after renal transplanta-
tion in patients with overt secondary hyperparathyroidism,
whereas smaller reductions were observed in those with normal
rates of bone formation (Fig. 2). In contrast to these findings,
serum PTH levels rose slightly after transplantation in patients
with adynamic renal osteodystrophy (Fig. 2). Serum phosphorus
and 1,25-dihydroxyvitamin D levels returned to normal after
transplantation in all patients, and post-transplant values did not
differ according to bone histology (data not shown). Similarly,
serum calcium levels did not differ among groups either before or
after renal transplantation.
Anthropometric measurements
Standard deviation scores for height (H-SDS) did not differ
according to bone histology in the 24 renal transplant recipients
who had bone mass determinations by DXA. The values were
22.1 6 1.1 for patients with normal bone formation (N 5 13),
22.2 6 0.9 for those with adynamic lesions (N 5 5) and 20.9 6
1.1 for subjects with secondary hyperparathyroidism (N 5 6).
There was no relationship between H-SDS and cumulative pred-
nisone dose (r 5 0.1, P 5 NS).
Bone mass determinations
Standard deviation scores for bone mineral content at the
lumbar spine averaged 20.67 6 1.2, and values did not differ
among those with secondary hyperparathyroidism, normal bone
formation or adynamic lesions. Bone mineral content was some-
what lower, however, in patients with normal bone formation (Fig.
3). As noted in previous work both in children and in adults [21,
22], z-scores for lumbar vertebral bone mineral content in indi-
vidual subjects correlated with height (r 5 0.69, P , 0.0005; Fig.
4A) and with weight (r 5 0.6, P , 0.001; Fig. 4B). After adjusting
for height, the average z-score for bone mineral content at the
lumbar spine was 0.68 6 1.0. Corrected values again did not differ
among the three histologic subgroups (Fig. 3). There was a
moderate correlation between serum alkaline phosphatase levels
and z-scores for bone mass at the lumbar spine (r 5 0.5, P 5
,0.05), but there was no relationship between cumulative pred-
nisone dose and bone mineral content (r 5 20.06) in pediatric
renal transplant recipients.
DISCUSSION
The results of the current investigation indicate that the skeletal
lesions of secondary hyperparathyroidism improve substantially in
pediatric patients undergoing successful renal transplantation, but
that bone histology does not fully revert to normal in many
transplant recipients. For patients with overt secondary hyper-
parathyroidism before transplantation, serum PTH levels often
Fig. 1. Bone histology in 24 patients initially
evaluated during maintenance dialysis and
again after successful kidney transplantation.
Abbreviations are 2°HPT, secondary
hyperparathyroidism; NL-BFR, normal bone
formation rate; AD, adynamic skeletal lesions.
Fig. 2. Serum parathyroid (PTH) levels at the time of bone biopsy in 24
patients evaluated during dialysis (u) and again after kidney transplan-
tation (f); subjects are grouped according to the initial histologic lesion.
*P , 0.004, secondary hyperparathyroidism (2°HPT) vs. normal bone
formation (NL-BFR) and adynamic skeletal lesions (AD).
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return to normal, tissue fibrosis resolves, and both bone resorp-
tion and bone formation decrease substantially after renal func-
tion is restored. Although adynamic bone is found in some
patients following kidney transplantation, the disorder is not
associated with high serum calcium levels that are often seen in
those with adynamic lesions undergoing regular dialysis [8, 23, 24].
Moreover, pediatric renal transplant recipients with adynamic
bone do not exhibit disproportionate reductions in bone mass
when assessed by dual energy X-ray absorptiometry (DXA).
Indeed, after adjusting for height to account for the degree of
growth retardation, bone mass was well-preserved an average of
four years after successful transplantation in most subjects in the
current study. Although serial measurements of bone mineral
content were not obtained in the current study, such findings
indicate that bone mass measurements using DXA must be
interpreted with caution in children with shortened stature due to
chronic renal disease, and they suggest that this technique may
overstate the prevalence and extent of osteoporosis in pediatric
renal transplant recipients.
Bone formation was normal after renal transplantation in the
majority of patients in the current study as judged by tetracycline-
based measurements in iliac crest bone biopsy specimens. Never-
theless, a number of these subjects demonstrated increases in
osteoid perimeter and in eroded bone perimeter in cancellous
bone. In some cases, such findings probably reflect a component
of persistent secondary hyperparathyroidism, since seven of 31
subjects with normal rates of bone formation had serum PTH
values above the upper limit of normal. In others, however, the
factors responsible for the increments in osteoid surface and
resorption surface remain uncertain. Cyclosporine has been re-
ported to increase both bone formation and bone resorption in
the rat and to reduce cancellous bone volume [11, 25], and similar
changes have been described in adult renal transplant recipients
[26]. The amount of trabecular bone was well-maintained, how-
ever, in nearly all subjects in the current study regardless of
histologic lesion. Thus, only two of 47 patients had values for
trabecular bone area below the lower limit of normal, and other
histologic indices of the micro-architectural integrity of cancellous
bone such as trabecular plate thickness (Tb. Th.) and trabecular
number (Tb. N.) did not differ substantially from normal.
For transplant recipients with bone biopsy evidence of second-
ary hyperparathyroidism, values for osteoid perimeter and eroded
bone perimeter were generally elevated, but marrow fibrosis was
absent. These are typical features of the mild lesion of secondary
hyperparathyroidism, and bone formation was above the upper
limit of normal in all patients in this subgroup [7]. Indeed, an
increase in bone formation is one of the criteria used to identify
the mild lesion of secondary hyperparathyroidism by the classifi-
cation scheme used by our laboratory [7]. Some patients with this
disorder, however, had serum PTH levels that fell within the
normal range. Thus, although PTH is generally considered to be
the major determinant of bone formation and turnover in patients
undergoing regular dialysis [27], it is likely that other factors also
influence osteoblastic activity in the post-transplant period. Treat-
ment with recombinant human growth hormone (rhGH) may
increase bone formation in some individuals [28], but none of the
subjects in the current study received rhGH. Cyclosporine is more
likely to account for higher rates of bone formation in patients
with normal serum PTH levels since prednisone and other
corticosteroids are usually associated with decreases rather than
increases in bone formation and turnover [29]. The role of other
immunosuppressive agents such as mycophenolate mofetil as
potential modifiers of bone formation and bone resorption has
not been evaluated.
Five of 47 renal transplant recipients had adynamic bone
Fig. 3. Uncorrected standard deviation scores (u) for bone mineral
content (BMC) by DXA (z-scores) and values corrected for height and age
(f). Subjects are grouped by histologic subtype after transplantation:
2°HPT, secondary hyperparathyroidism; NL-BFR, normal bone formation
rate; AD, adynamic skeletal lesions.
Fig. 4. (A) Relationship between height and bone mineral content (BMC)
in pediatric renal transplant patients (r 5 0.69, P < 0.0001). (B)
Relationship between weight and BMC in pediatric renal transplant
patients (r 5 0.66, P ,0.0004).
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documented by bone biopsy. Corticosteroids are generally
thought to contribute to the development of low-turnover skeletal
lesions after transplantation, and this may have been the case in
those patients with normal or high rates of bone formation prior
to transplantation [30]. In others, however, adynamic renal os-
teodystrophy was evident before transplantation, and bone for-
mation increased in two of these three subjects after renal
function was re-established. Such findings indicate that ongoing
therapy with prednisone and other immunosuppressive agents
does not preclude the restoration of normal osteoblastic activity
and bone formation in renal transplant recipients with pre-
existing adynamic renal osteodystrophy.
In the current study, trabecular bone area was greater in
subjects with secondary hyperparathyroidism than in those with
either normal bone formation or adynamic renal osteodystrophy.
Such findings confirm previous observations both in adults and in
children with renal secondary hyperparathyroidism, and they are
consistent with recent reports indicating that the amount of
cancellous bone is somewhat greater in patients with primary
hyperparathyroidism than in normal subjects [31, 32]. Increases in
the amount of trabecular bone have also been described in
patients with osteoporosis given intermittent doses of PTH ther-
apeutically [33, 34]. In this regard, Julian and co-workers observed
a decline in bone mass in the lumbar spine together with the
histologic resolution of secondary hyperparathyroidism during the
first six months after renal transplantation in adults [9]. Consid-
ering the higher cancellous bone volume documented in the
current and previous studies of patients with renal secondary
hyperparathyroidism, a portion of the reduction in vertebral bone
mineral content reported previously after renal transplantation
may be attributable to the resolution of secondary hyperparathy-
roidism in the immediate post-transplant period due to a loss of
the trophic effect of PTH on cancellous bone volume. The
magnitude of this change relative to other factors known to
adversely affect bone mass in the immediate post-transplant
period such as high-dose corticosteroid therapy and immobiliza-
tion will require careful further assessment.
Despite the use of recombinant human growth hormone
(rhGH) in children with renal disease, growth retardation remains
a major clinical problem in pediatric patients not only during
treatment with regular dialysis but also after renal transplantation.
As noted previously, none of the patients in the current study were
treated with rhGH, and z-scores for height were approximately
two SD units below age and gender appropriate mean values. Such
values are typical for pediatric patients with chronic renal disease
[35]. There were no differences, however, among histologic
subgroups in the degree of growth retardation after renal trans-
plantation in this subset of pre-pubertal children. Because bone
mass determinations using DXA are influenced not only by the
mineral content of bones but also by their size, variations in the
dimensions of bones can substantially affect the results [36, 37].
For subjects with growth retardation, values for bone mineral
content obtained by DXA using conventional methods will be
lower than expected for any given chronological age, at least in
part, because of the smaller size of the bones evaluated. When
results are compared to reference values obtained in persons of
the same age and sex without growth retardation to derive
standardized z-scores, lower values for bone mass in children with
short stature will partly reflect differences in bone size.
To account for the impact of short stature on the results of bone
mass determinations using DXA in renal transplant recipients, the
bone mineral content in each study subject, in g/cm2, was com-
pared to normal reference values for younger subjects of the same
height and gender to establish height-adjusted z-scores for lumbar
vertebral bone mineral content. The average height-adjusted
value of 0.68 6 1.0 obtained in this manner differed strikingly
from the conventional unadjusted z-score of 20.67 6 1.2 based
upon age-related comparisons provided by the manufacturer’s
software and reference database. As noted previously, trabecular
bone area was reduced in only two of 47 renal transplant
recipients by standard histologic criteria. These histomorphomet-
ric results support the contention that osteoporosis was not a
prominent feature in the renal transplant recipients enrolled in
the current study, and that height-adjusted rather than age-
adjusted z-scores for bone mass using DXA may serve as a better
index of the extent of bone loss in children with growth retarda-
tion due to chronic renal disease.
Renal transplantation corrects many of the metabolic and
hormonal abnormalities associated with renal failure and substan-
tially diminishes the skeletal manifestations of secondary hyper-
parathyroidism. The majority of subjects with well-functioning
renal transplants have normal rates of bone formation, but
increases in osteoid surface and in resorption surface persist in
cancellous bone in a substantial proportion of subjects. Adynamic
lesions of bone are less common, and the disorder may resolve
after successful renal transplantation in patients in whom this
skeletal lesion has developed during treatment with regular
dialysis. The results of the current study suggest that reductions in
bone mass and post-transplant osteoporosis are less common than
previously thought in pediatric renal transplant recipients when
the influence of growth retardation on bone mass measurements
using techniques such as dual energy X-ray absorptiometry is
carefully considered.
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APPENDIX
Abbreviations used in this article are: AD, adynamic skeletal lesions;
BMC, bone mineral content; DXA, dual energy X-ray absorptiometry;
GFR, glomerular filtration rate; HPT, hyperparathyroidism; H-SDS,
standard deviation scores for height; PTH, parathyroid hormone; rhGH,
recombinant human growth factor; SDS, standard deviation scores; Tb.
N., trabecular number; Tb. Th., trabecular plate thickness; Tx, transplan-
tation.
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